Ivonescimab Plus Chemotherapy in Patients with Initially Unresectable Colorectal Cancer Liver Metastases
The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aims to answer are:

Does ivonescimab plus chemotherapy raise the objective response rate? What medical problems do participants have when receiving ivonescimab plus chemotherapy?

Participants will:

Receive ivonescimab and chemotherapy every 3 weeks, no more than 8 cycles. Visit the clinic once every 2 cycles (6 weeks) for checkups and tests. Receive curative surgery, maintenance therapy, or discontinue study treatment according to the expert team's evaluation.
Colorectal Liver Metastases
DRUG: Ivonescimab plus chemotherapy
Objective Response Rate, At the end of Cycle 8 (each cycle is 21 days)|Treatment-Emergent Adverse Events, From the date of enrollment until 90 days after the Cycle 8 (each cycle is 21 days)
No evidence of disease rate, 6 months|Progression-free survival, From date of enrollment until the date of first documented progression, assessed up to 2 years|Overall Survival, From date of enrollment until the date of death, assessed up to 2 years|Recurrence-free survival, From the date of curative resection until the date of first documented progression, assessed up to 2 years|Disease control rate, At the end of Cycle 8 (each cycle is 21 days)|Treatment-related adverse events, From the date of enrollment until 90 days after the Cycle 8 (each cycle is 21 days)|Immunotherapy-related adverse events, From the date of enrollment until 180 days after the Cycle 8 (each cycle is 21 days)
The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aims to answer are:

Does ivonescimab plus chemotherapy raise the objective response rate? What medical problems do participants have when receiving ivonescimab plus chemotherapy?

Participants will:

Receive ivonescimab and chemotherapy every 3 weeks, no more than 8 cycles. Visit the clinic once every 2 cycles (6 weeks) for checkups and tests. Receive curative surgery, maintenance therapy, or discontinue study treatment according to the expert team's evaluation.